In another multicenter, open-label, single-arm phase II trial, the efficacy and safety profile of the combination of pertuzumab and trastuzumab were assessed in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy (Baselga et al., 2010). Here, ERBB2 is linked to breast carcinoma.